ArticleBlood advances2026
Characterization of a mouse model to study mechanisms of hemophilia A pain.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
abstractPain is a debilitating feature of hemophilia A (HA), yet it remains understudied. We developed models of chronic and acute pain in factor VIII knockout (FVIIIKO; B6;129S-FVIIItm1Kaz/J) mice, demonstrating characteristic features of hemarthrosis pain and gait. Using these models, we examined the mechanisms involving inflammation and vascular changes triggered by bleeding to produce pain. To recapitulate hemarthrosis, we used an acute knee-injury model to assess acute pain. We observed an increase in nocifensive behaviors, mechanical and deep tissue hyperalgesia, impaired weight bearing, and gait changes 4 days after subpatellar injury, which persisted through 8 weeks. The uninjured FVIIIKO mice showed similar changes in behaviors and gait at 10 weeks of age, suggestive of chronic pain. Dynamic gait changes indicated compensatory behavior. Hemarthropathy induced a significant elevation in circulating serum amyloid P and interleukin-6, and the injured knee joint showed a significant increase in neutrophil elastase, myeloperoxidase, mast cell degranulation, substance P (SP), and calcitonin gene-related peptide (CGRP), suggestive of global inflammation. SP and CGRP stimulate vascular permeability and arteriolar dilatation, respectively, but are also involved in the generation and maintenance of pain. Mast cell tryptase and neutrophil elastase activate protease-activated receptor 2, which causes nociceptor activation, leading to pain. Recombinant FVIII treatment led to partial improvement in pain behaviors. Thus, pain may persist after current HA treatments. Our study shows that a mouse model of HA can be used to study the mechanisms of pain and gait, which will enable us to develop treatable targets for pain in HA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.